| Project/Area Number |
21791509
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kochi University |
|---|
Principal Investigator |
FUKATA Satoshi Kochi University, 医学部附属病院, 医員 (80527599)
|
|---|
| Research Collaborator |
KARASHIMA Takashi 高知大学, 教育研究部医療学系, 助教 (60304672)
|
|---|
| Project Period (FY) |
2009 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2009: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 腎細胞癌 / AT1受容体拮抗剤(ARB) / 分子標的治療薬 / ATI受容体阻害剤(ARB) / 癌 / 発現制御 / AT1受容体阻害剤(ARB) |
|---|
| Research Abstract |
ARB used as hypotensive drug in place of general clinical. It was shown that there was the renal cell carcinoma proliferation action in our examination. It was assumed to be a purpose of the present study to clarify the cause and the process. In the result of review, it was thought that proliferation had the cytoprotective property by both carcinoma cells and normal cells under low oxygen, and appeared excessively in the cancer organization that was accentuation this action, and had brought ARB the cancer proliferation.
|
